ACTA congratulates ALLG on 50 years of clinical trials impact

Topics:ACTA Members

In October 2023, the Australian Leukaemia and Lymphoma Group (ALLG) celebrated their 50th anniversary during their annual scientific meeting.

As a long-standing ACTA member, we are incredibly proud to celebrate the significant and global impact that AALG have made to improve treatments and lives of people with blood cancer.

ACTA Board Director, Mr Kieran Schneemann, attended the celebration gala dinner which saw a panel interview with four previous Chairs of the ALLG Board, hosted by Professor Judith Trotman.

The event was a tribute to the group's collaborative success in clinical trials, leading to significant improvements in blood cancer treatment.

Professor Trotman is also a past Director of the ACTA Board and is an example of the true collaboration that occurs within the Australian clinical trials sector.

Congratulations ALLG.  We look forward to working together for many years to come.

Read more about ALLG’s 50 year celebration

Find out more about ALLG